News >

Expert Discusses Daratumumab Developments in Myeloma

Angelica Welch
Published: Thursday, Jul 05, 2018

Ajai Chari, MD

Ajai Chari, MD

Daratumumab (Darzalex) was shown to be safe and effective when added to the backbone of carfilzomib (Kyprolis) and dexamethasone in an analysis of patients with relapsed/refractory multiple myeloma enrolled on the phase Ib MMY1001 trial. Findings presented during the 2018 ASCO Annual Meeting signaled promising efficacy in patients who are refractory to lenalidomide (Revlimid), according to lead study author Ajai Chari, MD.

, Chari, associate professor, Mount Sinai Hospital, discussed the addition of daratumumab to carfilzomib and dexamethasone, as well as the potential impact of subcutaneous daratumumab in the treatment of patients with myeloma.

OncLive: Can you begin by giving some background information on MMY1001?

Chari: The purpose of MMY1001 was to show the safety of adding daratumumab to various myeloma backbone regimens. In this particular subgroup, there was an addition of daratumumab to carfilzomib and dexamethasone. 

The study showed that the addition of daratumumab did not add much to the safety profile of these other regimens. There was no synergistic or increased toxicity, with the only possible caveats being infusion-related toxicities from the monoclonal antibody administration. In some studies, there is a slightly higher rate of neutropenia, but typically without any associated increase in infections. 

What was the rationale for the analysis?

The rationale for the subgroup analysis—to look at the lenalidomide-refractory population—is basically coming from the fact that there is an increase in the use of lenalidomide maintenance after induction therapy and transplant due to the overall survival benefits reported. This means that the multiple large phase III studies that were published in high-impact journals, comparing triplet novel regimens with doublet control arms of lenalidomide/dexamethasone, would not apply to most patients who are refractory to these 2 agents. [In our study], we looked at patients who were refractory to lenalidomide see what the efficacy might be. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x